๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› France
Clinical trial register · European Union · CTIS

Clinical Trials in France

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 19 Sep 2026, 04:26 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42 Clear sponsor filter
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
49 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)
2025-521090-14-00Patients with relapsed/refractory symptomatic multiple myelโ€ฆ
Assistance Publique Hopitaux De Paris
Hemic and Lymphatic Diseases
France
08/04/2026
Phase III
โ€œIntravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicentre Randomized Controlled Trialโ€ THE IVT ALL IN TRIAL
2024-520414-21-00Adult patients with a LVOS with large core within 9 hours oโ€ฆ
Assistance Publique Hopitaux De Paris
Nervous System Diseases
France
12/03/2026
Phase III
CANDISHORT : A randomized study of a short duration therapy for candidemia
2024-514244-81-00Uncomplicated candidemia
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
06/03/2026
Phase III
APICALE - Cervical facet injection of corticosteroids for the management of cervicobrachialgia : protocol for a randomized pilot study
2024-511790-30-00Cervicobrachial Neuralgia
Assistance Publique Hopitaux De Paris
Nervous System Diseases
France
06/03/2026
Phase III
CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patients with Primary Bilateral Macronodular Adrenocortical Hyperplasia
2023-507010-27-00Primary Bilateral Macronodular Adrenal Hyperplasia causing โ€ฆ
Assistance Publique Hopitaux De Paris
Nutritional and Metabolic Diseases
France
05/03/2026
Phase III
TIC-TAC-SAM ยซ Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: a randomized trial ยป
2024-511807-41-01Hemophagocytic lymphohistiocytosis (HLH)
Assistance Publique Hopitaux De Paris
Pathological Conditions, Signs and Symptoms
France
27/02/2026
Phase II
STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients
2024-516215-24-00TAkayasu ARteritiS
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
26/02/2026
Phase III
Sustained-release oral morphine to alleviate persistent dyspnea in patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis outside the administration of ventilatory assistance: prospective multicenter randomized, placebo-controlled study, parallel arms. (OPIDYS-ALS).
2025-522546-52-00patients with chronic respiratory insufficiency due to amyoโ€ฆ
Assistance Publique Hopitaux De Paris
Respiratory Tract Diseases
France
13/02/2026
Phase III
Evaluation of the efficacy of corticosteroids in septic arthritis in adults: Randomized double-blind controlled trial [CORSAR]
2025-522193-37-00Septic arthritis
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
10/02/2026
Phase III
MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction
2025-523349-86-00Acute Myocardial Infarction
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
02/02/2026
Phase I/II
DREPAMIR - A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains autologous CD34+ cells transduced ex vivo by the bifunctional ฮฒAS3m/miR7m lentiviral vector expressing the ฮฒAS3m and a micro-RNA (miRNA) targeting specifically the endogenous ฮฒS-globin mRNA in Patients with Sickle Cell Disease (SCD)
2025-521257-17-00SCD severe patients
Assistance Publique Hopitaux De Paris
Hemic and Lymphatic Diseases
France
16/01/2026
Phase III
Fecal microbiota transplantation for primary sclerosing cholangitis - randomized study versus sham transplantation (FMT-SCLER).
2023-505469-95-00Primary Sclerosing Cholangitis
Assistance Publique Hopitaux De Paris
Nutritional and Metabolic Diseases
France
02/12/2025
Phase III
RASBU-SEPSIS Study: Effects of rasburicase on renal function during sepsis โ€“ a randomized, placebo-controlled, double-blind trial
2023-508071-36-00Patients hospitalised in intensive care, diagnosed with sepโ€ฆ
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
24/11/2025
Phase II
BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch
2024-514848-88-00Folliculitis decalvans
Assistance Publique Hopitaux De Paris
Therapeutics
France
24/11/2025
Phase II
PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial
2025-521371-31-00Sepsis
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
24/11/2025
Phase II
ALaDIN - Use of low doses of interleukin-2 in autism spectrum disorders
2025-522841-23-00Autism Spectrum disorder ASD
Assistance Publique Hopitaux De Paris
Mental Disorders
France
17/11/2025
Phase III
LEISURE : Lenalidomide vs methotrexate in difficult-to-treat cutaneous lupus erythematosus (LEISURE trial): An assessor-blinded randomized clinical trial
2024-520089-70-00Cutaneous lupus erythematosus
Assistance Publique Hopitaux De Paris
Skin and Connective Tissue Diseases
France
14/11/2025
Phase II
BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
2024-520308-24-00Adult patients with persistent dyspnea more than 3 months aโ€ฆ
Assistance Publique Hopitaux De Paris
Virus Diseases
France
24/10/2025
Phase III
SERORL Effect of aspirin and folic acid for sudden sensorineural hearing loss
2024-513710-35-00Patients presenting to ENT emergencies with a unilateral suโ€ฆ
Assistance Publique Hopitaux De Paris
Otorhinolaryngologic Diseases
France
17/10/2025
Phase II
CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders
2025-521161-27-00Children and adolescents with severe neurodevelopmental disโ€ฆ
Assistance Publique Hopitaux De Paris
Behavior and Behavior Mechanisms
France
07/10/2025
Phase IV
TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial
2025-520940-14-00Pyogenic liver abscess
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
06/10/2025
Phase II
CRYOBI study - A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious active cryoglobulinemia vasculitis refractory or intolerant to Rituximab
2023-508930-33-00Non-infectious active cryoglobulinemia vasculitis who are eโ€ฆ
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
02/10/2025
Phase I
CITY
2024-520294-13-00Cutaneous T-cell lymphomas (CTCL)
Assistance Publique Hopitaux De Paris
Skin and Connective Tissue Diseases
Spain, France
26/09/2025
Phase III
ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS. ANAPEM
2025-521478-32-00PEDIATRIC ACUTE MYOCARDITIS
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
04/09/2025
Rows per page Showing 26–49 of 49
Previous 1 2
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe/country/france

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.